Recon: Sanofi to buy Inhibrx for $2.2B; FDA pursues boxed warnings for CAR-T therapies

• White House pharmacy under the microscope (STAT)
• Pharma’s attack on Medicare drug price negotiation might benefit Biden (STAT)
• FDA seeks 'boxed warning' for CAR-T cancer therapies (Reuters) (Endpoints)
• J&J's Balversa gets mixed approval in bladder cancer as FDA ratchets up scrutiny on subgroup data, patient survival (Fierce Pharma)
• J&J, Legend's Carvykti bid for earlier multiple myeloma use will face FDA adcomm (Fierce Pharma)
• Johnson & Johnson still expects Carvykti to hit at least $5 bln peak sales -CFO (Reuters)

• Sanofi scoops up U.S. biotech Inhibrx for up to $2.2 billion as it seeks to bolster pipeline (STAT) (Endpoints) (Reuters)
• Can TikTok help boost lagging MMR vaccine uptake? UK politician believes a social media campaign could help (Fierce Pharma)
• Novo Nordisk continues to stack obesity pipeline, this time with Swiss zebrafish biotech (Endpoints)

• Merck inks deal with Unnatural Products; CG Oncology’s upsized IPO; Locus gets $24M from BARDA (Endpoints)
• J&J meets Q4 expectations with $21.4B in sales as it stares down patent cliff (Endpoints)
• J&J profit edges past Street view after deals delay Stelara competition (Reuters)
• Gene editing delivery biotech GenEdit partners with Genentech, raises another $24M (Endpoints)
• Turquoise Health raises $30M to use AI to sort through healthcare pricing data (Endpoints)
• Oncology biotech Accent raises $75M to enter the clinic (Endpoints)
• Autolus eyes November for potential US approval of Tecartus rival (Endpoints)
• Neuro companies are one of pharma's hottest M&A assets. But behind the scenes, there have been few bidders (Endpoints)
• Lilly’s Jaypirca tipped to capture 60% of BTK leukemia market, leaving AstraZeneca, BeiGene in the dust (Fierce Pharma)

• Mammograms are less effective for women with dense breast tissue. Medical experts disagree on what to do about it (STAT)
• What virtual physical therapy startup Hinge Health wants in M&A (Endpoints)
• Orthopedics leaders watch procedure backlog, new technologies in 2024 (MedTech Dive)
• J&J expects strong procedure volumes in 2024 (MedTech Dive)
• Edwards risks TAVR market share slip amid challenges from Abbott, Boston Scientific: survey (MedTech Dive)
• Fancy Making A Drug? You May Want To Create A Diagnostic First (MedTech Insight)
• Priority Projects For 2024 To Aid IVDR Implementation (MedTech Insight)
• News We’re Watching: Dexcom Expands In Ireland; Neurostim Updates From NANS; Novel Nanoparticles Treat Cancer In Mice; And More (MedTech Insight)

• Dana-Farber expands studies to be retracted to 6, plus 31 to be corrected over mishandled data (STAT)
• J&J agrees to resolve 42 US states' talc investigations (Reuters)
• Martin Shkreli's lifetime drug industry ban is upheld (Reuters)
• CDC says JN.1 variant accounts for about 86% of COVID cases in US (Reuters)